Please use this identifier to cite or link to this item:
Title: Human antibody responses to the meningococcal factor H binding protein (LP2086) during invasive disease, colonization and carriage.
Authors: Ala'aldeen, DA
Flint, M
Oldfield, NJ
Omer, SA
McNeil, LK
Jiang, Q
Murphy, E
Giardina, PC
Novikova, EG
Dodge-Scully, IL
Bayliss, CD
Turner, DP
Neal, KR
Hoiseth, SK
Jansen, KU
Anderson, AS
First Published: 10-Nov-2010
Citation: VACCINE, 2010, 28 (48), pp. 7667-7675
Abstract: Recombinant forms of Neisseria meningitidis factor H binding protein (fHBP) are undergoing clinical trials in candidate vaccines against serogroup B meningococcal disease. Little is known, however, about the host response to fHBP during natural carriage and disease. Here we report a longitudinal study of the antibody response to fHBP in healthy meningococcal carriers and non-carriers, and in patients with invasive meningococcal disease. Using a highly sensitive quantitative immunoassay, anti-fHBP antibodies were detected in sera from all healthy carriers and non-carriers. Carriers had significantly higher anti-fHBP antibody concentrations than non-carriers. Antibody responses similar to those seen in non-carrier subjects were detected in the sera of patients with invasive disease upon their admission to the hospital. The serum anti-fHBP antibody concentrations in these patients generally rose to reach levels similar to those seen in carriers. No correlation between levels of surface fHBP expressed in vitro by the infecting N. meningitidis strain and the magnitude of antibody responses was observed. These data suggest that fHBP is expressed in vivo during both carriage and invasive disease at levels high enough to elicit a robust antibody response.
DOI Link: 10.1016/j.vaccine.2010.09.038
eISSN: 1873-2518
Type: Journal Article
Appears in Collections:Published Articles, Dept. of Genetics

Files in This Item:
There are no files associated with this item.

Items in LRA are protected by copyright, with all rights reserved, unless otherwise indicated.